Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Sep;42(3):378–391. doi: 10.1038/bjc.1980.248

Chemotherapy of advanced malignant teratomas.

E S Newlands, R H Begent, S B Kaye, G J Rustin, K D Bagshawe
PMCID: PMC2010417  PMID: 7426343

Abstract

Between 1977 and November 1979 we have treated 53 patients with malignant teratomas (43 males, 10 females). Thirty (70%) out of the 43 male patients had advanced and bulky disease at the time of presentation. Using different drug combinations in a sequential manner as described below, results are as follows: of the initial 33 male patients, 22 (67%) have discontinued treatment (mean 9.5 months). Nineteen have responded completely and 3 have static computed tomography (CT) nodules. Life-table analysis projects a survival of 66% (analysis at 1 December 1979). Nine out of 10 ovarian teratoma patients are alive. Adverse prognostic factors at the start of treatment were recognized in 9/10 male patients and the 1 female patient who have died. Although the survival of patients with malignant teratomas has improved dramatically, there are still problems with drug resistance in patients with very advanced disease. Patients with these tumours should continue to be treated in centres specializing in managing what has now become a potentially curable disease in most cases.

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barzell W. E., Whitmore W. F., Jr Clinical significance of biologic markers: Memorial Hospital experience. Semin Oncol. 1979 Mar;6(1):48–52. [PubMed] [Google Scholar]
  2. Cangir A., Smith J., van Eys J. Improved prognosis in children with ovarian cancers following modified VAC (vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy. Cancer. 1978 Sep;42(3):1234–1238. doi: 10.1002/1097-0142(197809)42:3<1234::aid-cncr2820420331>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  3. Cheng E., Cvitkovic E., Wittes R. E., Golbey R. B. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer. 1978 Nov;42(5):2162–2168. doi: 10.1002/1097-0142(197811)42:5<2162::aid-cncr2820420512>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  4. Curry S. L., Smith J. P., Gallagher H. S. Malignant teratoma of the ovary: prognostic factors and treatment. Am J Obstet Gynecol. 1978 Aug 15;131(8):845–849. doi: 10.1016/s0002-9378(16)33128-3. [DOI] [PubMed] [Google Scholar]
  5. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  6. Golbey R. B., Reynolds T. F., Vugrin D. Chemotherapy of metastatic germ cell tumors. Semin Oncol. 1979 Mar;6(1):82–86. [PubMed] [Google Scholar]
  7. Hayes D. M., Cvitkovic E., Golbey R. B., Scheiner E., Helson L., Krakoff I. H. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977 Apr;39(4):1372–1381. doi: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Higby D. J., Wallace H. J., Jr, Albert D. J., Holland J. F. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974 May;33(5):1219–1215. doi: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Hong W. K., Wittes R. E., Hajdu S. T., Cvitkovic E., Whitmore W. F., Golbey R. B. The evolution of mature teratoma from malignant testicular tumors. Cancer. 1977 Dec;40(6):2987–2992. doi: 10.1002/1097-0142(197712)40:6<2987::aid-cncr2820400634>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  10. Javadpour N. The value of biologic markers in diagnosis and treatment of testicular cancer. Semin Oncol. 1979 Mar;6(1):37–47. [PubMed] [Google Scholar]
  11. Kardana A., Bagshawe K. D. A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin. J Immunol Methods. 1976;9(3-4):297–305. doi: 10.1016/0022-1759(76)90204-0. [DOI] [PubMed] [Google Scholar]
  12. LI M. C., WHITMORE W. F., Jr, GOLBEY R., GRABSTALD H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA. 1960 Nov 5;174:1291–1299. doi: 10.1001/jama.1960.03030100059013. [DOI] [PubMed] [Google Scholar]
  13. Lange P. H., McIntire K. R., Waldmann T. A., Hakala T. R., Fraley E. E. Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. N Engl J Med. 1976 Nov 25;295(22):1237–1240. doi: 10.1056/NEJM197611252952207. [DOI] [PubMed] [Google Scholar]
  14. Merrin C., Baumgartner G., Wajsman Z. Letter: Benign transformation of testicular carcinoma by chemotherapy. Lancet. 1975 Jan 4;1(7897):43–44. doi: 10.1016/s0140-6736(75)92411-3. [DOI] [PubMed] [Google Scholar]
  15. Newlands E. S., Bagshawe K. D. Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas. Lancet. 1977 Jul 9;2(8028):87–87. doi: 10.1016/s0140-6736(77)90088-5. [DOI] [PubMed] [Google Scholar]
  16. Newlands E. S., Dent J., Kardana A., Searle F., Bagshawe K. D. Serum alpha1-fetoprotein and H.C.G. in patients with testicular tumours. Lancet. 1976 Oct 2;2(7988):744–745. doi: 10.1016/s0140-6736(76)90044-1. [DOI] [PubMed] [Google Scholar]
  17. Peckham M. J., McElwain T. J., Barrett A., Hendry W. F. Combined management of malignant teratoma of the testis. Lancet. 1979 Aug 11;2(8137):267–270. doi: 10.1016/s0140-6736(79)90288-5. [DOI] [PubMed] [Google Scholar]
  18. Samson M. K., Stephens R. L., Rivkin S., Opipari M., Maloney T., Groppe C. W., Fisher R. Vinblastine, bleomycin, and cis-dichlorodiammineplatinum(II) in disseminated testicular cancer: preliminary report of a Southwest Oncology Group Study. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1663–1667. [PubMed] [Google Scholar]
  19. Samuels M. L., Holoye P. Y., Johnson D. E. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer. 1975 Aug;36(2):318–326. doi: 10.1002/1097-0142(197508)36:2<318::aid-cncr2820360205>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  20. Samuels M. L., Lanzotti V. J., Holoye P. Y., Boyle L. E., Smith T. L., Johnson D. E. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev. 1976 Dec;3(4):185–204. doi: 10.1016/s0305-7372(76)80009-6. [DOI] [PubMed] [Google Scholar]
  21. Scardino P. T., Cox H. D., Waldmann T. A., Mcintire K. R., Mittemeyer B., Javadpour N. The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol. 1977 Dec;118(6):994–999. doi: 10.1016/s0022-5347(17)58275-0. [DOI] [PubMed] [Google Scholar]
  22. Slayton R. E., Hreshchyshyn M. M., Silverberg S. C., Shingleton H. M., Park R. C., DiSalia P. J., Blessing J. A. Treatment of malignant ovarian germ cell tumors: response to vincristine, dactinomycin, and cyclophosphamide (preliminary report). Cancer. 1978 Aug;42(2):390–398. doi: 10.1002/1097-0142(197808)42:2<390::aid-cncr2820420203>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  23. Smithers D. W. Chemotherapy for metastatic teratomas of the testis. Br J Urol. 1972 Apr;44(2):217–228. doi: 10.1111/j.1464-410x.1972.tb10068.x. [DOI] [PubMed] [Google Scholar]
  24. Stoter G., Sleijfer D. T., Vendrik C. P., Schraffordt Koops H., Struyvenberg A., Van Oosterom A. T., Brouwers T. M., Pinedo H. M. Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma. Lancet. 1979 May 5;1(8123):941–945. doi: 10.1016/s0140-6736(79)91719-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES